Replies to post #244766 on Biotech Values

[dewophile]

Except if I’m getting bloods done anyway for say cholesterol it’s nice to throw in a screen for colon cancer. Bringing in a stool sample is a hassle. Doing a colonoscopy even bigger hassle. Obviously the latter is optimal and cologuard may be more sensitive but I bet this gets traction for ease of use.
No position

[DewDiligence]

EXAS—(+25%)—says “adjusted EBITDA” was positive in 4Q22 and will be positive in every quarter of 2023:

https://finance.yahoo.com/news/exact-sciences-announces-preliminary-fourth-204500863.html

Despite robust sales growth for Cologuard, EXAS has not yet turned profitable according to GAAP.

[DewDiligence]

GH—(-13%/AH)—discloses FDA advisory panel_for Shield liquid-biopsy for CRC:

https://www.businesswire.com/news/home/20231219982476/en

Diagnostics often don’t require an FDA advisory panel, so investors apparently think this is a negative development.

I maintain that a blood test cannot compete scientifically with a stool-based test such as Cologuard for detecting colorectal cancer and pre-cancer. However, a blood test has other advantages that may appeal to consumers.

See #msg-170708393 for related info.

[DewDiligence]

GH—FDA approves blood-based CRC diagnostic:

https://finance.yahoo.com/news/guardant-health-shield-blood-test-103000648.html

I’ve previously opined (#msg-173463096) that a blood test for colorectal cancer can’t match the sensitivity/specificity of a stool-based test such as EXAS’ Cologuard, particularly for precancerous lesions. However, the blood test is plainly more convenient.

In today's trading, GH is +3% and EXAS is -2%.